Navigation Links
CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
Date:12/3/2008

NEWNAN, Ga., Dec. 3 /PRNewswire/ -- CeloNova BioSciences, Inc., announced today that it has expanded the areas in which it is commercializing the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F -- a stent system that has not had any stent thrombosis in clinical studies. It is CE Marked and available for purchase throughout Europe and now some Middle Eastern countries with aggressive world-wide expansion ongoing. Concurrently, CeloNova notes that it has received regulatory approval to increase the shelf life for the stent from two years to three years.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081203/CLW056 )

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )

The CATANIA(TM) Polyzene(R)-F surface treatment is an inorganic polymer that confers superior biocompatibility and lubricity to the substrates it coats. The Polyzene(R)-F treated surface is anti-inflammatory, promotes quick and complete vessel healing, reduces peri-operative and post-procedural platelet activation, and helps to prevent tissue reactions that lead to restenosis.

"After having evaluated the Polyzene(R)-F coating many years ago, it is interesting to see this concept coming back with experimental and initial clinical data quite encouraging toward prevention of stent thrombosis," said Antonio Colombo, MD, Director of the Cardiac Catheterization Laboratory at Columbus Hospital and Chief of Invasive Cardiology at San Raffaele Hospital, both in Milan, Italy, who recently added the CATANIA(TM) stent to his practice.

The 1-year data for the first-in-man (FIM) presented at the recent Transcatheter Cardiovascular Therapeutics conference shows that at 12 months, in an unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent (five of 74 lesions analyzed at twelve months). Of note, all patients stopped dual anti-platelet therapy after 30 days, but continued aspirin (100 mg/d) throughout the 12-month period.

The acute angiographic and procedural success rate in the ATLANTA Trial was 100 percent. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound (IVUS) data for all patients immediately after stent implantation and at 6-month follow-up. Further analysis of 1,904 cross sections (19,028 struts) by investigators using Optimal Coherence Tomography at baseline and again at 6-month follow-up in a subset of 15 randomly selected patients revealed complete endothelialization and 99.5 percent stent strut coverage.

"We agree with Albert Einstein who said that we should strive to design solutions that are as simple as possible. The CATANIA(TM) stent, while it is superbly engineered to include the highly developed Polyzene(R)-F, is a simple solution to a complex problem. It has no drugs, no thick polymeric coating, no substance to artificially stimulate cell growth, and no additives. And, it does not force patients to take dual antiplatelet therapies for months on end, further complicating their lives," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. "The 'CAT(TM)' stent is an elegant, yet simple solution to the problem of clogged arteries."

For more information about CeloNova BioSciences, visit www.celonova.com. To place an order for the CATANIA(TM) stent, call +1 770-502-0304 to reach your local sales representative or e-mail info@celonova.com.

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit www.celonova.com.

About Polyzene(R)-F

Polyzene(R)-F is a synthesized inorganic chemical compound with an extensive array of bioscience and industrial applications that can be applied to or mixed with other substances to allow for a diverse range of bioscience and industrial applications on a multitude of substrates, including other polymers, metals, and ceramics. Medical devices coated with Polyzene(R)-F do not cause a negative reaction in the body when introduced, eliciting a normalized and positive bodily response. Polyzene(R)-F can be customized for the desired application and applied in a variety of ways including as a coating, extrusion, weaving, or electro-spinning ranging in thickness from less than 40 nanometers to more than 200 nanometers. The base substrate will be endowed with the properties of the polymer.

CONTACT: Robert J. Murphy

              The Storch-Murphy Group
              908-276-0777


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
2. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
3. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
6. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
7. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
8. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
9. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
10. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
11. BBM Announces Offer to Acquire YM BioSciences Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small cell lung ... limited tumor content in a large background of normal or wild type cells. ... for reliable detection of low abundance somatic mutations, particularly in small specimens with ...
(Date:3/27/2017)... NC (PRWEB) , ... March 27, 2017 , ... ... Clinical Trial Collaborations (CTC) conference presented by The Conference Forum in Boston on ... way they collaborate to drive improved clinical trial outcomes and bring them closer to ...
(Date:3/24/2017)... , March 24, 2017 MiMedx Group, ... company utilizing human placental tissue allografts and patent-protected processes ... multiple sectors of healthcare, announced today  that it will ... New York , NY.  Parker H. "Pete" Petit, ... Financial Officer, Christopher M. Cashman , EVP and ...
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, Inc. ... company, today announced that Richard Peterson will ... 24.   Peterson, who brings more than two ... Smither , who is retiring at the end of ... advisory capacity. Peterson joins Sienna from Novan, Inc., where ...
Breaking Biology Technology:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
Breaking Biology News(10 mins):